Venadaparib hydrochloride  (Synonyms: IDX-1197 hydrochloride)

Venadaparib (IDX-1197) hydrochloride is a potent and selective PARP inhibitor with anticancer activities. Venadaparib hydrochloride can be used for solid tumors research^[1][2].

Venadaparib (example 143; 6-10 days) shows potent growth inhibition of MDA-MB-436 cells and Capan-1 pancreatic cancer cells with IC₅₀ values of ≤5nM and 50nM [2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In the germline BRCA1-mutated ovarian cancer PDX model, oral administration of Venadaparib (IDX-1197) exhibits significant PAR inhibition (>90%) in tumor tissues until 24 hr post dose. Venadaparib also dose-dependently led to potent tumor growth inhibition compared to Olaparib treatment group^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

442.91

C₂₃H₂₄ClFN₄O₂

1681020-60-9

O=C1NN=C(CC2=CC=C(F)C(C(N3CC(CNC4CC4)C3)=O)=C2)C5=C1C=CC=C5.[H]Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yong Man Kim, et al. First-in-human dose-finding study of venadaparib (IDX-1197), a potent and selective PARP inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology. 39, no. 15_suppl (May 20, 2021) 3107-3107.

  [2]. Jae-Hoon Kang, et al. A novel phtalazinone derivatives and manufacturing process thereof. WO2015037939A1.